Literature DB >> 9586150

[Marfan syndrome: prevalence and natural course of cardiovascular manifestations].

Y von Kodolitsch1, M Raghunath, C A Nienaber.   

Abstract

The Marfan syndrome is an autosomal dominant disorder of the connective tissue with mutations on the fibrillin-1 gene encoding for fibrillin, a major component of the extracellular microfibrils. The prevalence of the syndrome is 7-17/100,000. The mean life expectancy for untreated patients with Marfan syndrome is 32 years with aortic dissection, aortic rupture or cardiac failure due to mitral and aortic valve regurgitation as the predominant cause of death in > 90% of the cases. In severely affected cases with neonatal Marfan syndrome, patients are likely to survive only a few months. According to the literature database the prevalence of aortic dilatation is 76%, 26% for aortic regurgitation, 62% for mitral valve prolapse, and 29% for mitral valve regurgitation in adult patients with classic Marfan syndrome. Pathogenesis and the natural cause of each cardiovascular manifestation is thoroughly discussed with the problems resulting from associated cardiac arrhythmias, sudden cardiac death, endocarditis, and less frequent cardiovascular manifestations of the Marfan syndrome. Special focus is placed on the analysis of cardiovascular complications during pregnancy.

Entities:  

Mesh:

Year:  1998        PMID: 9586150     DOI: 10.1007/s003920050167

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  5 in total

1.  Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues.

Authors:  Russell A Norris; Brook Damon; Vladimir Mironov; Vladimir Kasyanov; Anand Ramamurthi; Ricardo Moreno-Rodriguez; Thomas Trusk; Jay D Potts; Richard L Goodwin; Jeff Davis; Stanley Hoffman; Xuejun Wen; Yukiko Sugi; Christine B Kern; Corey H Mjaatvedt; Debi K Turner; Toru Oka; Simon J Conway; Jeffery D Molkentin; Gabor Forgacs; Roger R Markwald
Journal:  J Cell Biochem       Date:  2007-06-01       Impact factor: 4.429

Review 2.  The role of the multidisciplinary health care team in the management of patients with Marfan syndrome.

Authors:  Yskert von Kodolitsch; Meike Rybczynski; Marina Vogler; Thomas S Mir; Helke Schüler; Kerstin Kutsche; Georg Rosenberger; Christian Detter; Alexander M Bernhardt; Axel Larena-Avellaneda; Tilo Kölbel; E Sebastian Debus; Malte Schroeder; Stephan J Linke; Bettina Fuisting; Barbara Napp; Anna Lena Kammal; Klaus Püschel; Peter Bannas; Boris A Hoffmann; Nele Gessler; Eva Vahle-Hinz; Bärbel Kahl-Nieke; Götz Thomalla; Christina Weiler-Normann; Gunda Ohm; Stefan Neumann; Dieter Benninghoven; Stefan Blankenberg; Reed E Pyeritz
Journal:  J Multidiscip Healthc       Date:  2016-11-03

3.  A Case of Neonatal Marfan Syndrome: A Management Conundrum and the Role of a Multidisciplinary Team.

Authors:  Elliott J Carande; Samuel J Bilton; Satish Adwani
Journal:  Case Rep Pediatr       Date:  2017-01-11

4.  A Case Report of Marfan Syndrome Presenting With Atypical Chest Pain: A 28-Year-Old Male With Non-ST-Elevation Myocardial Infarction (NSTEMI).

Authors:  Tayyab Cheema; Malek Balek; Patrick Smith; Saad Hanan
Journal:  Cureus       Date:  2022-02-08

Review 5.  Current role of endovascular therapy in Marfan patients with previous aortic surgery.

Authors:  Ibrahim Akin; Stephan Kische; Tim C Rehders; Tushar Chatterjee; Henrik Schneider; Thomas Körber; Christoph A Nienaber; Hüseyin Ince
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.